The phase 2 ICON trial reveals that iberdomide combined with low-dose cyclophosphamide and dexamethasone (IberCd) achieves a median PFS of 17.6 months in lenalidomide-refractory multiple myeloma. This all-oral regimen represents a significant advancement in convenience and efficacy for heavily pretreated patients.